CN204219578U - Containing the coating in blood vessel sacculus of Thalidomide layer - Google Patents
Containing the coating in blood vessel sacculus of Thalidomide layer Download PDFInfo
- Publication number
- CN204219578U CN204219578U CN201420304470.2U CN201420304470U CN204219578U CN 204219578 U CN204219578 U CN 204219578U CN 201420304470 U CN201420304470 U CN 201420304470U CN 204219578 U CN204219578 U CN 204219578U
- Authority
- CN
- China
- Prior art keywords
- sacculus
- coating
- layer
- push rod
- thalidomide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
This utility model provides a kind of coating in blood vessel sacculus containing Thalidomide layer, comprise medication coat and balloon body, medication coat is coated on balloon body on the surface, and coating comprises: be coated at least one deck Thalidomide layer on balloon body and be coated on coating outermost macromolecule poly nitride layer.At least one deck Thalidomide layer is provided with in the coating of the coating in blood vessel sacculus that this utility model provides, make this sacculus in Selective depression Ink vessel transfusing smooth muscle cell hyper-proliferative and injured blood vessel inflammatory reaction, thus the generation of the postoperative restenosis of stenter to implant can be prevented and treated.
Description
Technical field
This utility model relates to cardiac vascular medical field, especially, relates to a kind of coating in blood vessel sacculus containing Thalidomide layer.
Background technology
In PCI post-surgical vascular, restenosis is a complexity, multifactorial pathophysiological process, after sacculus and support injured blood vessel, make tunica intima and medial smooth muscle cells that migration and propagation occur under the effect of inflammatory factor, platelet factor and somatomedin, simultaneously a large amount of extracellular matrixs is piled up in tunica intima and damage location, causes neointimal hyperplasia and causes in-stent restenosis.Wherein inflammatory reaction causes in-stent restenosis major reason, and main manifestations is synthesis and the release of PCI post-operation inflammatory cell aggregation and infiltration and inflammatory factor.The effect of inflammatory reaction in vascular restenosis is formed is familiar with gradually by people, adjustment inflammatory factor level has important meaning to vascular restenosis, people resist the propagation of VSMC and migration, anti-inflammatory drug support have carried out the research of dark people, also achieve certain achievement.The mechanism of the coating stent of medicine anti-restenosis such as current discovery sirolimus and paclitaxel also reacts relevant with inflammation-inhibiting.
Medicinal balloon (Drug Coated Balloon) is a kind of take conduit as the delivery device sent, and this Objective Concept Harvey Wolinsky proposed in 1991, is used for the vascular restenosis after preventing blood saccule dilatation.The balloon body that intravascular drug sacculus adopts macromolecular material to make is as pharmaceutical carrier, after balloon body on the surface load have therapeutical effect medicine, by this medicinal balloon volume-diminished to catheter surface, by conduit, medicinal balloon is delivered to blood vessel target lesion place, once inflation is adopted to make sacculus instantaneous expansion again, thus by the drug delivery on balloon body surface to narrow and expansion after arterial intima on, reach local orientation's administration.The medicine that balloon surface is coated with is when arriving diseased region, and make balloon expandable diseased region by pressurization dilating sacculus, the medicine be simultaneously coated with carries out sustained release at this, makes the generation of the abundant ingestion of drugs of blood vessel wall and then suppression restenosis.Medicine-coated balloon be by medicine directly or by suitable support coating in balloon surface, make sacculus become a local drug delivery system.Its mechanism of action suppresses the hyperplasia of tunica intima, medicine-coated balloon method need not carry out radiotherapy, sometimes also can not implant frame, without polymer or other release tech continued, drug conveying just can be made to arrive all regions reached by sacculus.
At present, the current mainly taxol medicament elution sacculus of known medicament elution sacculus, existing clinical test results display taxol drug sacculus compared with common sacculus, late tube chamber lose, the aspect such as restenosis rate and major cardiovascular events rate, medicinal balloon is all better than common sacculus.But its coating medicine is unselected cell drug toxicity, existing coating medicine is after suppression inner film injury while smooth muscle cell hyper-proliferative, also migration and the propagation of endotheliocyte can be affected, and obvious inflammatory effect can be produced at injured blood vessel, thus cause the problem of the complete and Delayed onset Thrombosis in sten of support endothelialization.Therefore develop a kind of Selective depression Ink vessel transfusing smooth muscle cell and suppress the medicine-coated balloon of injured blood vessel inflammatory reaction may have important clinical meaning to reducing PCI postoperative restenosis and improving reconstructing blood vessel curative effect.
Thalidomide (Thalidomide) has another name called phthalein miaow croak smack one's lips ketone, phthalein phthalimide base penta 2 phthalein amine, and trade name reaction stops, and molecular structure is two phthalimide rings, and molecular weight is 258.233.Thalidomide is the vomiting being used to treat pregnancy women as tranquilizer at first, but withdraws from the market because causing serious fetal anomaly.Research afterwards finds that Thalidomide has immunoregulation effect, inhibiting angiogenesis effect, antiinflammatory action and be again applied to clinical treatment immune disease, malignant tumor, disease in the blood system etc.The expression of Thd to multiple inflammatory factor is inhibited, as TNF α, ILs, COX-2, TGF β etc.The anti-inflammatory mechanisms of Thalidomide is considered to main relevant with its suppression I-κ B Phosphorylation events.Also have report recently, it can suppress high fat diet atherosclerotic rabbit pathological changes to be formed, and the hypertrophy of new intima after balloon injury of rat carotid arteries can be suppressed.Liu Lushan, 17 (1), Chinese arteriosclerosis magazine, 4-8 (2009); Sun Shougang, 36 (6), the sick magazine of international cardiovascular, 393-396 (2009).Also Thalidomide is by reducing the TNF α of transplanted abdominal and the expression of PCNA albumen, suppresses smooth muscle cell proliferation and migration, thus alleviates transplanted abdominal progression of fibrosis and neointimal hyperplasia to have scholar to find.Xu Ziqiang, 6 (2), magazine (electronic edition) is transplanted by China, 125-129 (2012).
Research both domestic and external shows that Thalidomide is as inflammation antagonist, is mainly used in the treatment such as tumor and immune disease field, for the propagation of inhibition tumor cell and the inflammatory reaction of tissue.Recently studies have found that Thalidomide can suppress smooth muscle cell proliferation and neointimal hyperplasia, Stent restenosis do not suppressed to Thalidomide in prior art and carried out investigation and application containing the situation of Thalidomide composite coating support.
Utility model content
This utility model object is to provide a kind of intravascular drug coating sacculus containing Thalidomide layer, not only to suppress smooth muscle cell proliferation but also the medicine-coated balloon of antagonize inflammatory reaction.
For achieving the above object, provide a kind of coating in blood vessel sacculus according to this utility model, comprise balloon body and coating, coating is coated on balloon body on the surface, and coating comprises: be coated at least one deck Thalidomide layer on balloon body.
Further, can comprise macromolecule poly nitride layer, macromolecule poly nitride layer is coated on coating outermost layer.
Further, described macromolecule poly nitride layer is at least one deck heparin layer.
Further, described macromolecule poly nitride layer is heparin layer.
Further, coating layer thickness is 5-10 μm.
Further, coating layer thickness is 8 μm.
Further, balloon body is PVC sacculus, PE sacculus, PET and nylon copolymer sacculus or PET sacculus etc.
Further, comprise far-end push rod, near-end push rod, expansion inflation inlet and guidewire port, balloon body is be coated on the first end of near-end push rod with shrinking, and the first end of near-end push rod is closed; Expansion inflation inlet is tee T, and the second end of near-end push rod is communicated with a mouth of expansion inflation inlet, and another mouthful of expansion inflation inlet is connected with the first end of far-end push rod, and the second end of far-end push rod is connected with guidewire port 5.
Further, expansion inflation inlet comprise the logical first that is connected with each other, second mouthful and the 3rd mouthful, the expansion first of inflation inlet is connected with the second end of near-end push rod, expands the 3rd mouthful of inflation inlet and is connected with the first end of far-end push rod.
Further, the surface being contained in the near-end push rod in balloon body arranges multiple interior rod aperture, interior rod aperture is communicated with the inner inside with near-end push rod of balloon body.
This utility model has following beneficial effect:
At least one deck Thalidomide layer is provided with in the coating of the coating in blood vessel sacculus that this utility model provides, make this sacculus can suppress Ink vessel transfusing smooth muscle cell proliferation and suppress inflammatory reaction after blood vessel injury, thus the generation of antagonism in-stent restenosis and the vascular repair after promoting damage.The macromolecule poly nitride layer be simultaneously coated on Thalidomide layer can reduce the loss that Thalidomide medicine is unnecessary before arriving target lesion, can prevent the thrombosis on intravascular balloon surface simultaneously.
Except object described above, feature and advantage, this utility model also has other object, feature and advantage.Below with reference to figure, this utility model is described in further detail.
Accompanying drawing explanation
The accompanying drawing forming a application's part is used to provide further understanding of the present utility model, and schematic description and description of the present utility model, for explaining this utility model, is not formed improper restriction of the present utility model.In the accompanying drawings:
Fig. 1 is this utility model preferred embodiment schematic side view; And
Fig. 2 is this utility model preferred embodiment partial cutaway schematic.
Marginal data:
1, balloon body; 2, Thalidomide layer; 3, heparin layer; 21, far-end push rod; 6, inflation inlet is expanded; 4, near-end push rod; 41; Interior rod aperture; 5, guidewire port.
Detailed description of the invention
Below in conjunction with accompanying drawing, embodiment of the present utility model is described in detail, but the multitude of different ways that this utility model can be defined by the claims and cover is implemented.
This utility model provides a kind of coating in blood vessel sacculus, and this coating sacculus comprises at least one deck Thalidomide layer (phthalein miaow croak smack one's lips ketone).Thalidomide can be, but not limited to chemical synthesis routinely and obtains.Method as provided in CN02146050.7 can prepare.Bracket coating medicine comprises Thalidomide, but is not limited to Thalidomide, also comprises thalidomide derivatives or analog etc.Thalidomide of the present invention can use separately or with combination with other therapeutic agents, curative as T suppression cell comprises following medicine, but be not limited thereto, as: rapamycin, protaxel, taxanes, docetaxel, macrolide immunosuppressant, macrolide antibiotic, zotaroliums, novolimus, sirolimus, than Ao Mosi (biolimus), myolimus, deforolimus, azoles Luo Mosi, tacrolimus or CCI-779 compound, the structural derivative of rapamycin and functional analogue, everolimus and structural derivative thereof and functional analogue, azoles Luo Mosi, everolimus, sirolimus, myolimus, deforolimus, the structural derivative of tacrolimus or CCI-779 compound and functional analogue etc.The coating coating of drug delivery balloon of the present invention being configured at least 25% shifts from balloon surface in two minutes after inflation.The coating that this utility model provides can adopt conventional method to be coated on coating bracket body, such as can adopt coating self assembly, immerse seasoning, multilamellar construction from part etc.According to the present invention, by following technique, coating is applied to sacculus: such as dip-coating, electrostatic spraying, electrostatic spinning, injection coating, imbibition coating, gas help spraying, piezoelectricity spraying, directly liquid application or other method known to those skilled in the art.Coating can be applied at least part of or whole sacculus.Balloon body is in sacculus leading portion.Balloon structure can for conventional balloon structure as WO 2013097717 A1, CN 202538130 balloon structure disclosed in U all can be used in this utility model.
The coating drug excipient of sacculus coating of the present invention is preferably water miscible.Excipient can comprise nonionic hydrophilic polymer.Nonionic hydrophilic polymer includes, but are not limited to: polyvinylpyrrolidone (PVP), silk elastin-like polymer, polyvinyl alcohol, Polyethylene Glycol (PEG), pluronic (PEO-PPO-PEO), polyethylene glycol oxide (PEO), PEG phospholipid, PVP-vinyl acetate (copovidone), polyvinyl acetate and polysorbate are as polysorbate20 (Tween 20).The molecular weight of preferred nonionic hydrophilic polymer can be less than 100kDa, to impel rapid solution.Can be preferred, there is the polyvinylpyrrolidone (PVP) of below 100kDa molecular weight, with the mucoadhesive providing faster release coat and increase blood vessel wall.PVP be by N-vinyl-2-pyrrole the water-soluble polymer that generates of alkane one monomers catalysis, soluble in water and ethanol etc.When aquation, inflatable formation can water-soluble release and adhere to the drug release coating of blood vessel.Excipient also can be or comprises contrast agent in addition, and described contrast agent includes, but are not limited to Iopromide (Ultravist), Ioxaglate (Hexabrix), Iopamidol (Isovue), Iotrolan Ioversol (Optiray), Diatrixoate (Conray) and Iodixanol (Visipque) etc.And wherein preferred, the hydrophilic contrast agent of lower molecular weight (< 1000Da) such as Iopromide (Ultravist) can reach the releasing effect that drug release and coating blood vessel faster adhere to.
This utility model can adopt sacculus administration as shown in Figure 1.Sacculus is bar.Sacculus comprises balloon body 1, far-end push rod 21, near-end push rod 4, expansion inflation inlet 31, guidewire port 5.Balloon body 1 is made for expandable material.Contraction state is in before unaerated.Balloon body 1 is coated on the first end of near-end push rod 4.One end of balloon body 1 is fixed on the first end of near-end push rod 4.Near-end push rod 4 first end is closed.The other end of balloon body 1 is fixed on near-end push rod 4 sidewall.The near-end push rod 4 be contained in balloon body 1 arranges multiple interior rod aperture 41 on the surface.Interior rod aperture 41 is through hole.Interior rod aperture 41 is communicated with the inside of balloon body 1 inside and near-end push rod 4.Second end of near-end push rod 4 is communicated with expansion inflation inlet 31.Gas passes in near-end push rod 4 by expansion inflation inlet 31, and is entered in balloon body 1 by interior rod aperture 4, thus balloon body 1 is expanded instantaneous administration.Expansion inflation inlet 31 is tee T.Expansion inflation inlet 31 comprise first, second mouthful and the 3rd mouthful.Second end of near-end push rod 4 is connected with the first of expansion inflation inlet 31.Second mouthful of expansion inflation inlet 31 can pass into gas or closedown.The 3rd mouthful of expansion inflation inlet 31 is connected with the first end of far-end push rod 21.Second end of far-end push rod 21 is connected with guidewire port 5.The first of expansion inflation inlet 31 is communicated with the 3rd mouthful of horizontal saliva is flat.Can close when inflating for 3rd mouthful.Guidewire port 5 can pass into seal wire (not shown) can by guided by saccule extremely to snack made with traditional Chinese medicines by seal wire.Seal wire enters rear through far-end push rod 21 and near-end push rod 4 until the top of balloon body 1 from guidewire port 5.Under balloon body 1 contraction state, length is 10-30mm.Also can be provided with 20-40 slight conical groove on surface under balloon body 1 contraction state used, each depression volume and distribution are uniform, and when arranging layer, groove can improve the band dose of sacculus, improve the dosage once expanded.When sacculus uses, inflate to balloon body 1, make its instantaneous expansion, now cone-shaped groove outwardly, and the medicine assembled in groove is injected into affected part, plays a role.Concrete structure is listed by WO 2013097717 A1.
The structure of certain sacculus also can be on the sidewall of balloon proximal push rod 4, offer through hole concrete structure as listed by CN 202538130 U.Impact on blood perfusion when adopting the sacculus of above-mentioned two kinds of structures can improve the performance efficiency of drug effect and reduce drug release while administration.
The coating that the coating sacculus that this utility model provides comprises balloon body 1 and is coated on this balloon body 1 surface.Coating comprises at least one deck Thalidomide layer 2.After coating in blood vessel balloon body 1 Surface coating Thalidomide layer 2 (or containing excipient), energy Selective depression Ink vessel transfusing smooth muscle cell proliferation and antagonizing vessel inflammatory reaction, promote damaged blood vessels reparation, avoid the generation of postoperative restenosis.Drug excipient can comprise nonionic hydrophilic polymer, is preferably the nonionic hydrophilic polymer that molecular weight is less than 100kDa, is more preferably the polyvinylpyrrolidone (PVP) with below 100kDa MW; Preferred coating also can comprise and is coated on coating outermost macromolecule poly nitride layer.Macromolecule poly nitride layer for conventional sacculus top layer macromolecule poly nitride layer, can be preferably chitosan layer, gelatin layer, PLGA (Poly(D,L-lactide-co-glycolide) layer or heparin layer.Be more preferably heparin layer.Heparin layer can be heparin sodium (or calcium) layer or low molecular sodium heparin (or calcium) layer or heparinization macromolecule polymer.Macromolecule poly nitride layer can avoid the medicine on Thalidomide layer 2 in the process being delivered to target lesion place, not occur unnecessary loss, and prevent medicine and excipient thereof from release occurring too early before balloon expandable and adheres to, heparin type coating can also play anticoagulation simultaneously, prevents the outer thrombosis of sacculus.
Macromolecule poly nitride layer is preferably heparin layer or heparinization macromolecule polymer, during using heparin layer or heparinization macromolecule polymer as outermost layer, gained coating balloon surface is more smooth, the outer thrombosis of sacculus can be avoided, and reduce medicine loss before releasing, be conducive to sacculus coating Chinese medicine and arrive target site performance drug effect.
Specifically can be, as shown in Figure 2, this coating in blood vessel sacculus comprises: balloon body 1, Thalidomide layer (or containing excipient) 2 and heparin layer 3.Coating balloon body 1 Surface coating Thalidomide layer 2.Coated heparin layer 3 on Thalidomide layer 2 outer surface.Bulk coat thickness is 5-10 μm, and preferably now coating layer thickness is 8 μm.
Balloon body can be made for conventional balloon material.Also PVC (polrvinyl chloride) sacculus, PE (crosslinked polyethylene) sacculus, PET (polyethylene terephthalate) and nylon copolymer sacculus or PET sacculus can be preferably for smash capsule, low pressure sacculus, compliant balloon, non-compliance sacculus, half compliant balloon.Sacculus can also be nylon balloons, Pebax (nylon elastomer) sacculus, block polyether acidamide resin sacculus.
Below illustrate the preparation method of Thalidomide and coating sacculus, the coating sacculus preparation method that this utility model provides is not limited thereto.
Illustrate coating in blood vessel sacculus preparation method:
Embodiment 1 comprises the following steps:
1) PVP of the Thalidomide and 30mg that take 70mg is dissolved in acetone and the water (acetone: water=7.5:1) of 4ml, at ambient temperature, with vibration incubator jolting to dissolving and after being uniformly dispersed, being mixed with medicinal balloon coating solution;
2), under room temperature, Pebax sacculus is soaked in the acrylic acid aqueous solution of 1mol/L in 10min, vacuum drying; By above-mentioned solution spraying in balloon surface, dry, folding, can obtain medicinal balloon, balloon pressure remains on 1.2Psi, and high pure nitrogen synchronously solidifies, until the drug loading on balloon body reaches 200-400 μ g/cm
2;
3) the sacculus utricule of coating is placed in the dry 10-15 hour of vacuum drying oven, and drying condition is: vacuum is-0.2Mpa, temperature is 15-18 DEG C;
4) be immersed in 0.1% heparin sodium aqueous solution by above-mentioned sacculus after surface treatment, in drying baker, nitrogen dries up (drug loading is about 100 μ g/ piece);
5) carry out sacculus to be connected with head end, then sacculus utricule is folded; Assembly and connection far-end push rod, changeover portion, near-end push rod; Assembling HUB sheath handle obtains containing Thalidomide medicinal balloon after balloon body surface being arranged the sacculus assembling of medication coat.
Embodiment 2 comprises the following steps:
1) solution of 100mg Thalidomide and contrast agent Iopromide 1g/20ml proportions is by weight percentage taken, at ambient temperature, with the jolting of vibration incubator to dissolving and after being uniformly dispersed, being mixed with medicinal balloon coating solution;
2), under room temperature, PVC sacculus is soaked in the acrylic acid aqueous solution of 1mol/L in 10min, vacuum drying; By above-mentioned solution spraying in balloon surface, dry, folding, can obtain medicinal balloon, balloon pressure remains on 1.2Psi, and high pure nitrogen synchronously solidifies, until the drug loading on balloon body reaches 200-400 μ g/cm
2;
3) the sacculus utricule of coating is placed in the dry 10-15 hour of vacuum drying oven, and drying condition is: vacuum is-0.2Mpa, temperature is 15-18 DEG C;
4) be immersed in 0.1% heparin sodium aqueous solution by above-mentioned sacculus after surface treatment, in drying baker, nitrogen dries up (drug loading is about 100 μ g/ piece);
5) obtain containing Thalidomide medicinal balloon after balloon body surface being arranged the sacculus assembling of medication coat.
Embodiment 3 comprises the following steps:
1) PEG (Mw < 5000) taking 70mg Thalidomide and 50mg is dissolved in the acetone of 4ml and ethanol (acetone: ethanol=3:1) and forms mixed liquor, at ambient temperature, with vibration incubator jolting to dissolving and after being uniformly dispersed, being mixed with medicinal balloon coating solution;
2), under room temperature, nylon based sacculus is carried out X-ray process 3min; By above-mentioned solution spraying in balloon surface, dry, folding, can obtain medicinal balloon, balloon pressure remains on 1.2Psi, and high pure nitrogen synchronously solidifies, until the drug loading on balloon body reaches 200-400 μ g/cm
2;
3) the sacculus utricule of coating is placed in the dry 10-15 hour of vacuum drying oven, and drying condition is: vacuum is-0.2Mpa, temperature is 15-18 DEG C;
4) be immersed in 0.1% heparin sodium aqueous solution by above-mentioned sacculus after surface treatment, in drying baker, nitrogen dries up (drug loading is about 100 μ g/ piece);
5) obtain containing Thalidomide medicinal balloon after balloon body surface being arranged the sacculus assembling of medication coat.
Embodiment 4 comprises the following steps:
1) PVP of the Thalidomide and 30mg that take 70mg is dissolved in acetone and the water (acetone: water=7.5:1) of 4ml, at ambient temperature, with vibration incubator jolting to dissolving and after being uniformly dispersed, being mixed with medicinal balloon coating solution;
2), under room temperature, Pebax sacculus is soaked in the acrylic acid aqueous solution of 1mol/L in 10min, vacuum drying; By above-mentioned solution spraying in balloon surface, dry, folding, can obtain medicinal balloon, balloon pressure remains on 1.2Psi, and high pure nitrogen synchronously solidifies, until the drug loading on balloon body reaches 200-400 μ g/cm
2;
3) the sacculus utricule of coating is placed in the dry 10-15 hour of vacuum drying oven, and drying condition is: vacuum is-0.2Mpa, temperature is 15-18 DEG C;
4) by the mass ratio of 4:10, heparin is dissolved in the gelatin solution that mass percent is 4%, is immersed in heparin isinglass solution by above-mentioned sacculus after surface treatment, in drying baker, nitrogen dries up (heparin drug loading is about 100 μ g/ piece);
5) carry out sacculus to be connected with head end, then sacculus utricule is folded; Assembly and connection far-end push rod, changeover portion, near-end push rod; Assembling HUB sheath handle obtains containing Thalidomide medicinal balloon after balloon body surface being arranged the sacculus assembling of medication coat.
The foregoing is only preferred embodiment of the present utility model, be not limited to this utility model, for a person skilled in the art, this utility model can have various modifications and variations.All within spirit of the present utility model and principle, any amendment done, equivalent replacement, improvement etc., all should be included within protection domain of the present utility model.
Claims (10)
1., containing a coating in blood vessel sacculus for Thalidomide layer, comprise balloon body and coating, described coating is coated on described balloon body on the surface, it is characterized in that, described coating comprises: be coated at least one deck Thalidomide layer on described balloon body.
2. sacculus according to claim 1, is characterized in that, sacculus coating can comprise macromolecule poly nitride layer, and described macromolecule poly nitride layer is coated on described coating outermost layer.
3. sacculus according to claim 2, is characterized in that, described macromolecule poly nitride layer is at least one deck heparin layer.
4. sacculus according to claim 1, is characterized in that, described macromolecule poly nitride layer is heparin layer.
5. sacculus according to claim 4, is characterized in that, described coating layer thickness is 5-10 μm.
6. sacculus according to claim 5, is characterized in that, described coating layer thickness is 8 μm.
7. the sacculus according to any one of claim 1-6, is characterized in that, described balloon body is PE sacculus, PVC sacculus, PET and nylon copolymer sacculus or PET sacculus etc.
8. sacculus according to claim 7, it is characterized in that, comprise far-end push rod, near-end push rod, expansion inflation inlet and guidewire port, described balloon body is be coated on the first end of described near-end push rod with shrinking, and the first end of described near-end push rod is closed; Described expansion inflation inlet is tee T, and the second end of near-end push rod is communicated with a mouth of expansion inflation inlet, and another mouthful of expansion inflation inlet is connected with the first end of far-end push rod, and the second end of far-end push rod is connected with guidewire port 5.
9. sacculus according to claim 8, it is characterized in that, described expansion inflation inlet comprise the logical first that is connected with each other, second mouthful and the 3rd mouthful, the first of described expansion inflation inlet is connected with the second end of near-end push rod, and the 3rd mouthful of described expansion inflation inlet is connected with the first end of far-end push rod.
10. sacculus according to claim 9, is characterized in that, the surface being contained in the described near-end push rod in described balloon body arranges multiple interior rod aperture, and described interior rod aperture is communicated with the inner inside with near-end push rod of balloon body.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420304470.2U CN204219578U (en) | 2014-06-10 | 2014-06-10 | Containing the coating in blood vessel sacculus of Thalidomide layer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201420304470.2U CN204219578U (en) | 2014-06-10 | 2014-06-10 | Containing the coating in blood vessel sacculus of Thalidomide layer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204219578U true CN204219578U (en) | 2015-03-25 |
Family
ID=52917726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201420304470.2U Expired - Fee Related CN204219578U (en) | 2014-06-10 | 2014-06-10 | Containing the coating in blood vessel sacculus of Thalidomide layer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204219578U (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922784A (en) * | 2015-07-01 | 2015-09-23 | 乐普（北京）医疗器械股份有限公司 | Drug balloon catheter |
| CN112494785A (en) * | 2020-12-03 | 2021-03-16 | 广东博迈医疗器械有限公司 | Balloon catheter with novel structure |
| CN114225119A (en) * | 2016-02-08 | 2022-03-25 | 祥丰医疗私人有限公司 | Inflatable balloon containing coating |
| US11559671B2 (en) | 2016-02-08 | 2023-01-24 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
-
2014
- 2014-06-10 CN CN201420304470.2U patent/CN204219578U/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922784A (en) * | 2015-07-01 | 2015-09-23 | 乐普（北京）医疗器械股份有限公司 | Drug balloon catheter |
| CN114225119A (en) * | 2016-02-08 | 2022-03-25 | 祥丰医疗私人有限公司 | Inflatable balloon containing coating |
| US11559671B2 (en) | 2016-02-08 | 2023-01-24 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
| CN112494785A (en) * | 2020-12-03 | 2021-03-16 | 广东博迈医疗器械有限公司 | Balloon catheter with novel structure |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12214107B2 (en) | Drug-coated medical devices | |
| CN103736154B (en) | Medicinal coating balloon catheter | |
| CN104623740B (en) | A kind of medicinal balloon and preparation method thereof | |
| CN103948975B (en) | A kind of targeted drug release gets involved class medical apparatus and instruments and preparation method thereof | |
| CN103561791B (en) | Be coated with the distensible devices of paclitaxel composition | |
| CN104399132B (en) | Drug coated balloon catheter and Pharmacokinetic Characteristics | |
| EP2886136B1 (en) | A Coated Angioplasty or Coronary Angioplasty Catheter | |
| EP2982389B1 (en) | Encapsulated drug compositions and methods of use thereof | |
| CN110201243B (en) | Composite drug coating balloon catheter and preparation method thereof | |
| CN102258811B (en) | Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open | |
| JP5443336B2 (en) | Stent with biodegradable layer | |
| CN204219578U (en) | Containing the coating in blood vessel sacculus of Thalidomide layer | |
| JP6533229B2 (en) | Long-acting rims preparation for balloon catheters | |
| CN101365447A (en) | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions | |
| CN104936629A (en) | Drug coated balloon catheters for nonvascular strictures | |
| CN113975594B (en) | Drug coating balloon and preparation method thereof | |
| CN105833358B (en) | A kind of intracranial drug-eluting stent system and preparation method thereof | |
| EP3884987A1 (en) | Drug eluting balloon and balloon catheter | |
| CN102940543A (en) | Combined medical instrument formed by drug coated balloon and stent | |
| CN106806948B (en) | Use of dual PI3K/mTOR inhibitors | |
| WO2023083086A1 (en) | Drug-coated and drug-eluting balloon catheter, and preparation method therefor | |
| CN201734994U (en) | Medicine-loading coronal artery bracket capable of loading medicine in the manner of gradient concentration | |
| CN107754022A (en) | A kind of medication coat and preparation method thereof | |
| CN107865868B (en) | New application of amlexanox | |
| CN101496813B (en) | Application of composition in preparing medicine coating of anti-tissue proliferation (vascular restenosis) stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150325 Termination date: 20190610 |